Payment overview · 2025
General Payments
$238.57
13 reported records · 5 companies
Healthcare provider profile · identity verified
Ajay Patel, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CLANTON, AL · NPI 1235247412
Verified facts
What the public records show
CMS Open Payments records show Ajay Patel, M.D. received $238.57 in general payments during 2025 across 13 reported records.
Novo Nordisk Inc accounted for 38.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 176 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $90.78 | 38.0% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $50.23 | 21.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $48.06 | 20.1% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.78 | 13.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.72 | 7.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $238.57 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $61.46 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $61.46 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $50.23 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $48.06 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $32.78 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 176 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
176 | 46 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 532 | 197 |
| Losartan Potassium | Losartan Potassium | 513 | 206 |
| Amlodipine Besylate | Amlodipine Besylate | 468 | 182 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 451 | 123 |
| Gabapentin | Gabapentin | 384 | 131 |
| Famotidine | Famotidine | 375 | 179 |
| Levothyroxine Sodium | Levothyroxine Sodium | 337 | 133 |
| Pantoprazole Sodium | Pantoprazole Sodium | 287 | 118 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 282 | 54 |
| Tramadol Hcl | Tramadol Hcl | 260 | 76 |
| Lisinopril | Lisinopril | 258 | 100 |
| Metformin Hcl | Metformin Hcl | 256 | 95 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 255 | 119 |
| Omeprazole | Omeprazole | 232 | 86 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 227 | 86 |
| Trazodone Hcl | Trazodone Hcl | 201 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 192 | 80 |
| Tamsulosin Hcl | Tamsulosin Hcl | 187 | 62 |
| Ozempic | Semaglutide | 176 | 46 |
| Allopurinol | Allopurinol | 174 | 69 |
| Eliquis | Apixaban | 170 | 41 |
| Baclofen | Baclofen | 167 | 97 |
| Tizanidine Hcl | Tizanidine Hcl | 165 | 75 |
| Duloxetine Hcl | Duloxetine Hcl | 163 | 67 |
| Furosemide | Furosemide | 162 | 68 |
| Metoprolol Tartrate | Metoprolol Tartrate | 159 | 66 |
| Januvia | Sitagliptin Phosphate | 156 | 49 |
| Meloxicam | Meloxicam | 143 | 62 |
| Carvedilol | Carvedilol | 141 | 55 |
| Metformin Hcl Er | Metformin Hcl | 139 | 63 |
| Clopidogrel | Clopidogrel Bisulfate | 122 | 45 |
| Potassium Chloride | Potassium Chloride | 121 | 52 |
| Alprazolam | Alprazolam | 112 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 112 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 112 | 45 |
| Clonazepam | Clonazepam | 109 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 49 |
| Glipizide | Glipizide | 106 | 46 |
| Simvastatin | Simvastatin | 100 | 30 |
| Azithromycin | Azithromycin | 97 | 89 |
| Mounjaro | Tirzepatide | 97 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 96 | 36 |
| Hydralazine Hcl | Hydralazine Hcl | 95 | 41 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 94 | 28 |
| Cefdinir | Cefdinir | 93 | 83 |
| Ondansetron Hcl | Ondansetron Hcl | 92 | 42 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 92 | 31 |
| Buspirone Hcl | Buspirone Hcl | 91 | 42 |
| Atenolol | Atenolol | 90 | 37 |
| Paroxetine Hcl | Paroxetine Hcl | 90 | 34 |
| Prednisone | Prednisone | 86 | 57 |
| Clonidine Hcl | Clonidine Hcl | 82 | 37 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 74 | 28 |
| Montelukast Sodium | Montelukast Sodium | 71 | 30 |
| Spironolactone | Spironolactone | 68 | 28 |
| Farxiga | Dapagliflozin Propanediol | 63 | 27 |
| Methylprednisolone | Methylprednisolone | 63 | 57 |
| Sertraline Hcl | Sertraline Hcl | 61 | 26 |
| Dicyclomine Hcl | Dicyclomine Hcl | 60 | 32 |
| Donepezil Hcl | Donepezil Hcl | 60 | 30 |
| Topiramate | Topiramate | 57 | 25 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 56 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 35 |
| Ezetimibe | Ezetimibe | 54 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 54 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 20 |
| Xarelto | Rivaroxaban | 53 | suppressed |
| Pregabalin | Pregabalin | 52 | 16 |
| Memantine Hcl | Memantine Hcl | 51 | 21 |
| Naproxen | Naproxen | 51 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | 19 |
| Mirtazapine | Mirtazapine | 49 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 19 |
| Finasteride | Finasteride | 46 | 20 |
| Lorazepam | Lorazepam | 46 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | 22 |
| Meclizine Hcl | Meclizine Hcl | 45 | 31 |
| Propranolol Hcl | Propranolol Hcl | 45 | 18 |
| Fluconazole | Fluconazole | 44 | 38 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | 16 |
| Promethazine Hcl | Promethazine Hcl | 43 | 13 |
| Celecoxib | Celecoxib | 41 | 20 |
| Glipizide Er | Glipizide | 41 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 32 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 29 |
| Ondansetron Odt | Ondansetron | 37 | 26 |
| Colestipol Hcl | Colestipol Hcl | 36 | 17 |
| Synthroid | Levothyroxine Sodium | 36 | 16 |
| Nystatin | Nystatin | 35 | 21 |
| Cefuroxime | Cefuroxime Axetil | 34 | 32 |
| Valacyclovir | Valacyclovir Hcl | 34 | 20 |
| Azelastine Hcl | Azelastine Hcl | 33 | 17 |
| Levofloxacin | Levofloxacin | 33 | 30 |
| Amiodarone Hcl | Amiodarone Hcl | 32 | 12 |
| Levetiracetam | Levetiracetam | 32 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 30 |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Telmisartan | Telmisartan | 31 | 20 |
| Warfarin Sodium | Warfarin Sodium | 31 | 13 |
| Sucralfate | Sucralfate | 30 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | 11 |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 26 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 25 | 15 |
| Nitroglycerin | Nitroglycerin | 25 | 14 |
| Ramipril | Ramipril | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 24 | 11 |
| Levemir Flexpen | Insulin Detemir | 24 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 21 |
| Glimepiride | Glimepiride | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | 12 |
| Rybelsus | Semaglutide | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | 11 |
| Divalproex Sodium | Divalproex Sodium | 21 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Gemtesa | Vibegron | 19 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 19 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $238.57 · 13 records | Novo Nordisk Inc | Dexcom G6 Transmitter, Kerendia, Ozempic, Rybelsus, The Cologuard Plus Collection Kit, Wegovy, XIFAXAN | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error